

Alerta Bibliográfica 190317

1. NA HS, Kwon JE, Lee SH, Jhun J, et al.
Th17/IL-17 Cause Acceleration of Inflammation and Fat Loss by Inducing alpha2-Glycoprotein 1 (AZGP1) in Rheumatoid Arthritis with High-Fat Diet.
Am J Pathol. 2017 Mar 8. pii: S0002-9440(17)30210.
PubMed: www.amedeo.com/p2.php?id=28284716&s=rhe&pm=352014ef2974a30
ABSTRACT available
Share: m.amedeo.com/28284716
2. RAMIRO S, Sepriano A, Chatzidionysiou K, Nam JL, et al.
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis.
Ann Rheum Dis. 2017 Mar 15. pii: annrheumdis-2016-210708.
PubMed: www.amedeo.com/p2.php?id=28298374&s=rhe&pm=352014ef2974a30
ABSTRACT available
Share: m.amedeo.com/28298374
3. DERKSEN VF, Ajeganova S, Trouw LA, van der Helm-van Mil AH, et al.
Rheumatoid arthritis phenotype at presentation differs depending on the number of autoantibodies present.
Ann Rheum Dis. 2016;76:716-720.
PubMed: www.amedeo.com/p2.php?id=28283528&s=rhe&pm=352014ef2974a30
ABSTRACT available
Share: m.amedeo.com/28283528
4. BAKER JF, Ostergaard M, Conaghan PG.
Is MRI a predictive biomarker for clinical response to biologics in rheumatoid arthritis?
Ann Rheum Dis. 2017 Mar 10. pii: annrheumdis-2017-211265.
PubMed: www.amedeo.com/p2.php?id=28283517&s=rhe&pm=352014ef2974a30
Share: m.amedeo.com/28283517
5. SEWERIN P, Vordenbaeumen S, Brinks R, Ostendorf B, et al.
Prospective MRI score to predict negative EULAR response in patients with rheumatoid arthritis (RA) before therapy-escalation to a biological therapy.
Ann Rheum Dis. 2017 Mar 10. pii: annrheumdis-2017-211257.
PubMed: www.amedeo.com/p2.php?id=28283516&s=rhe&pm=352014ef2974a30
Share: m.amedeo.com/28283516
6. NAM JL, Takase-Minegishi K, Ramiro S, Chatzidionysiou K, et al.
Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis.

Ann Rheum Dis. 2017 Mar 10. pii: annrheumdis-2016-210713.
PubMed: www.amedeo.com/p2.php?id=28283512&s=rhe&pm=352014ef2974a30
ABSTRACT available
Share: m.amedeo.com/28283512

7. CAPORALI R, Carletto A, Conti F, D'Angelo S, et al.
Using a modified Delphi process to establish clinical consensus for the
diagnosis, risk assessment and abatacept treatment in patients with aggressive
rheumatoid arthritis.
Clin Exp Rheumatol. 2017.
PubMed: www.amedeo.com/p2.php?id=28281459&s=rhe&pm=352014ef2974a30
ABSTRACT available
Share: m.amedeo.com/28281459

8. DAGAN A, Kogan M, Shoenfeld Y, Segal G, et al.
When uncommon and common coalesce: adult onset Still's disease associated
with
breast augmentation as part of autoimmune syndrome induced by adjuvants (ASIA).
Clin Rheumatol. 2016;35:1643-8.
PubMed: www.amedeo.com/p2.php?id=25604318&s=rhe&pm=352014ef2974a30
ABSTRACT available
Share: m.amedeo.com/25604318

9. COHEN S, Kay J.
Biosimilars: implications for rheumatoid arthritis therapy.
Curr Opin Rheumatol. 2017 Mar 16. doi: 10.1097/BOR.0000000000000379.
PubMed: www.amedeo.com/p2.php?id=28306596&s=rhe&pm=352014ef2974a30
ABSTRACT available
Share: m.amedeo.com/28306596

10. SAITO S, Kaneko Y, Izumi K, Takeuchi T, et al.
Utility of Dose Frequency Adjustment in Tocilizumab Administration for Rheumatoid
Arthritis.
J Rheumatol. 2017 Mar 15. pii: jrheum.161047. doi: 10.3899/jrheum.161047.
PubMed: www.amedeo.com/p2.php?id=28298563&s=rhe&pm=352014ef2974a30
ABSTRACT available
Share: m.amedeo.com/28298563

11. DE ANDRADE NP, da Silva Chakr RM, Xavier RM, Viaceli D, et al.
Long-term outcomes of treat-to-target strategy in established rheumatoid
arthritis: a daily practice prospective cohort study.
Rheumatol Int. 2017 Mar 14. doi: 10.1007/s00296-017-3695.
PubMed: www.amedeo.com/p2.php?id=28293776&s=rhe&pm=352014ef2974a30
ABSTRACT available
Share: m.amedeo.com/28293776

12. KUUSALO L, Puolakka K, Kautiainen H, Karjalainen A, et al.

Patient-reported outcomes as predictors of remission in early rheumatoid arthritis patients treated with tight control treat-to-target approach.
Rheumatol Int. 2017 Mar 13. doi: 10.1007/s00296-017-3692.
PubMed: www.amedeo.com/p2.php?id=28289873&s=rhe&pm=352014ef2974a30
ABSTRACT available
Share: m.amedeo.com/28289873

13. BARRETT O, Abramovich E, Dreier J, Novack V, et al.
Short- and long-term mortality due to sepsis in patients with rheumatoid arthritis.
Rheumatol Int. 2017 Mar 12. doi: 10.1007/s00296-017-3694.
PubMed: www.amedeo.com/p2.php?id=28286904&s=rhe&pm=352014ef2974a30
ABSTRACT available
Share: m.amedeo.com/28286904

14. VALOR L, Martinez-Estupinan L, Janta I, Nieto JC, et al.
Ultrasound-detected joint inflammation and B cell count: related variables for rituximab-treated RA patients?
Rheumatol Int. 2016;36:793-7.
PubMed: www.amedeo.com/p2.php?id=27072348&s=rhe&pm=352014ef2974a30
ABSTRACT available
Share: m.amedeo.com/27072348

15. DOMINGUEZ-MOZO MI, Toledano-Martinez E, Rodriguez-Rodriguez L, Garcia-Montojo M, et al.
JC virus reactivation in patients with autoimmune rheumatic diseases treated with rituximab.
Scand J Rheumatol. 2016;45:507-511.
PubMed: www.amedeo.com/p2.php?id=27063911&s=rhe&pm=352014ef2974a30
ABSTRACT available
Share: m.amedeo.com/27063911

16. BALLESTER C, Grobost V, Roblot P, Pourrat O, et al.
Pregnancy and primary Sjogren's syndrome: management and outcomes in a multicentre retrospective study of 54 pregnancies.
Scand J Rheumatol. 2017;46:56-63.
PubMed: www.amedeo.com/p2.php?id=27191226&s=rhe&pm=352014ef2974a30
ABSTRACT available
Share: m.amedeo.com/27191226

17. KOH JH, Kwok SK, Lee J, Son CN, et al.
Pain, xerostomia, and younger age are major determinants of fatigue in Korean patients with primary Sjogren's syndrome: a cohort study.
Scand J Rheumatol. 2017;46:49-55.
PubMed: www.amedeo.com/p2.php?id=27098775&s=rhe&pm=352014ef2974a30
ABSTRACT available
Share: m.amedeo.com/27098775